HCA Healthcare, Inc. has reported its fourth-quarter 2025 results and provided guidance for 2026. In the fourth quarter of 2025, the company's revenues increased by 6.7% to $19.513 billion compared to the same quarter in 2024. Net income attributable to HCA Healthcare, Inc. also saw a significant increase of 30.6% to $1.878 billion, with diluted earnings per share increasing by 44.6% to $8.14 per share. Adjusted EBITDA for the same period increased by 10.8% to $4.114 billion.
For the full year ended December 31, 2025, HCA Healthcare, Inc. reported total revenues of $75.600 billion, marking a 6.7% increase from the previous year. Net income attributable to the company was $6.784 billion, or $28.33 per diluted share, compared to $5.760 billion, or $22.00 per diluted share, for the year ended December 31, 2024.
The company's balance sheet as of December 31, 2025, reflected cash and cash equivalents of $1.040 billion, total debt of $46.492 billion, and total assets of $60.720 billion. Additionally, HCA Healthcare, Inc. repurchased 5.432 million shares of its common stock at a cost of $2.558 billion during the fourth quarter of 2025.
Looking ahead, the company has issued its estimated guidance for 2026, with revenues projected to range between $76.500 billion to $80.000 billion. Net income attributable to HCA Healthcare, Inc. is estimated to be in the range of $6.495 billion to $7.035 billion, and adjusted EBITDA is forecasted to be between $15.550 billion to $16.450 billion. The company also declared a quarterly cash dividend of $0.78 per share on its common stock, payable on March 31, 2026, to stockholders of record at the close of business on March 17, 2026.
These figures indicate a positive trend for HCA Healthcare, Inc., as the company has experienced notable increases in key financial metrics compared to the previous periods. Following these announcements, the company's shares moved -3.0%, and are now trading at a price of $469.29. If you want to know more, read the company's complete 8-K report here.
